×

Calithera Biosciences to Present at the 15th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 08, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 15th Annual Needham Healthcare Conference. William D. Waddill, Senior Vice President and Chief Financial Officer will present on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time at The Westin New York Grand Central Hotel in New York, NY.

About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.

Contact: Jennifer McNealey ir@Calithera.com 650-870-1071

Source:Calithera Biosciences, Inc.